D.E. Furst

2.3k total citations
48 papers, 1.6k citations indexed

About

D.E. Furst is a scholar working on Pathology and Forensic Medicine, Rheumatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, D.E. Furst has authored 48 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pathology and Forensic Medicine, 21 papers in Rheumatology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in D.E. Furst's work include Systemic Sclerosis and Related Diseases (21 papers), Rheumatoid Arthritis Research and Therapies (17 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (8 papers). D.E. Furst is often cited by papers focused on Systemic Sclerosis and Related Diseases (21 papers), Rheumatoid Arthritis Research and Therapies (17 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (8 papers). D.E. Furst collaborates with scholars based in United States, United Kingdom and France. D.E. Furst's co-authors include Vibeke Strand, Jeffrey D. Greenberg, Marco Matucci‐Cerinic, George Reed, Joel M. Kremer, J. Randall Curtis, Karolyn Au, James R. Seibold, Maureen D. Mayes and Peter A. Merkel and has published in prestigious journals such as Annals of the Rheumatic Diseases, American Journal of Roentgenology and Clinical Pharmacology & Therapeutics.

In The Last Decade

D.E. Furst

48 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D.E. Furst United States 20 908 545 418 411 292 48 1.6k
Paul Maranian United States 25 1.1k 1.2× 498 0.9× 323 0.8× 333 0.8× 415 1.4× 43 1.8k
Emmanuel Chatelus France 19 723 0.8× 410 0.8× 377 0.9× 314 0.8× 282 1.0× 55 1.5k
Luís J. Catoggio Argentina 21 694 0.8× 1.1k 2.0× 730 1.7× 204 0.5× 248 0.8× 53 1.8k
Antonio Carletto Italy 22 481 0.5× 797 1.5× 620 1.5× 200 0.5× 170 0.6× 133 2.0k
A Akesson Sweden 22 1.1k 1.3× 274 0.5× 301 0.7× 502 1.2× 404 1.4× 43 1.7k
Zora Marjanovic France 22 907 1.0× 171 0.3× 454 1.1× 264 0.6× 297 1.0× 79 2.3k
Giovanni Pomponio Italy 17 360 0.4× 325 0.6× 345 0.8× 108 0.3× 190 0.7× 50 1.3k
P Maddison United Kingdom 20 357 0.4× 983 1.8× 385 0.9× 119 0.3× 113 0.4× 38 1.6k
Carina Mihai Romania 18 714 0.8× 200 0.4× 198 0.5× 296 0.7× 339 1.2× 73 1.2k
Alain Le Quellec France 19 282 0.3× 219 0.4× 235 0.6× 110 0.3× 264 0.9× 35 1.1k

Countries citing papers authored by D.E. Furst

Since Specialization
Citations

This map shows the geographic impact of D.E. Furst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.E. Furst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.E. Furst more than expected).

Fields of papers citing papers by D.E. Furst

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.E. Furst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.E. Furst. The network helps show where D.E. Furst may publish in the future.

Co-authorship network of co-authors of D.E. Furst

This figure shows the co-authorship network connecting the top 25 collaborators of D.E. Furst. A scholar is included among the top collaborators of D.E. Furst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D.E. Furst. D.E. Furst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bruni, Cosimo, Silvia Bellando-Randone, Serena Guiducci, et al.. (2017). FRI0380 Patient preferences and difficulties concerning the home treatment options in systemic sclerosis (SSC). Annals of the Rheumatic Diseases. 76. 631–631. 1 indexed citations
2.
3.
Genovese, M. C., Patrick Durez, Roy Fleischmann, et al.. (2016). Olokizumab Treatment of both Western and Asian Patients with Rheumatoid Arthritis who have Failed Anti-Tnf Treatment Results in Sustained Improvements in Patient-Reported Outcomes. Value in Health. 19(7). A543–A544. 2 indexed citations
4.
Furst, D.E., Sangmee Bae, P. Clements, et al.. (2014). Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. Lara D. Veeken. 54(1). 144–151. 25 indexed citations
5.
Furst, D.E., et al.. (2012). Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population. Lupus. 22(1). 99–105. 49 indexed citations
6.
Avouac, Jérôme, Dörte Huscher, D.E. Furst, Oliver Distler, & Yannick Allanore. (2012). OP0226 Expert consensus for performing right heart catheterization in suspicion of pulmonary arterial hypertension associated with systemic sclerosis: A delphi consensus study with cluster analysis from the eposs group. Annals of the Rheumatic Diseases. 71. 132–132. 6 indexed citations
7.
Au, Karolyn, George Reed, J. Randall Curtis, et al.. (2011). High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 70(5). 785–791. 248 indexed citations
8.
Frech, Tracy, Ron D. Hays, Paul Maranian, et al.. (2011). Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study. Lara D. Veeken. 50(7). 1280–1287. 44 indexed citations
9.
Sokolove, Jeremy, Vibeke Strand, Jeffrey D. Greenberg, et al.. (2010). Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 69(9). 1612–1617. 71 indexed citations
10.
Avouac, Jérôme, Otylia Kowal‐Bielecka, David Pittrow, et al.. (2010). Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Annals of the Rheumatic Diseases. 69(7). 1360–1363. 32 indexed citations
11.
Matucci‐Cerinic, Marco, CP Denton, D.E. Furst, et al.. (2010). Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases. 70(1). 32–38. 322 indexed citations
12.
Avouac, Jérôme, Jaap Fransen, U.A. Walker, et al.. (2010). Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Annals of the Rheumatic Diseases. 70(3). 476–481. 286 indexed citations
13.
Khanna, Dinesh, Chi‐Hong Tseng, D.E. Furst, et al.. (2009). Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study. Lara D. Veeken. 48(12). 1537–1540. 33 indexed citations
14.
15.
Sullivan, K., D. H. Wallace, Peter A. McSweeney, et al.. (2008). Gastric antral vascular ectasia (GAVE) in early diffuse SSc: Report from the SCOT trial. Arthritis & Rheumatism. 58(9). 3 indexed citations
16.
Khanna, Dhanita, Daniel J. Lovell, Edoardo G. Giannini, et al.. (2007). Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Annals of the Rheumatic Diseases. 67(5). 703–709. 62 indexed citations
17.
Furst, D.E., et al.. (1997). Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation.. PubMed. 48. 85–8. 26 indexed citations
18.
Furst, D.E., et al.. (1994). DC-ART: decreased inflammatory synovitis.. PubMed. 41. 27–35. 2 indexed citations
19.
Furst, D.E., et al.. (1987). Salicylate toxicity in elderly patients with rheumatoid arthritis.. PubMed. 14(1). 60–6. 20 indexed citations
20.
Furst, D.E., et al.. (1984). Case control study of antibodies to ENA in progressive systemic sclerosis patients.. PubMed. 11(3). 298–305. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Maranian Breakdown of academic impact, for papers by Emmanuel Chatelus Breakdown of academic impact, for papers by Luís J. Catoggio Breakdown of academic impact, for papers by Antonio Carletto Breakdown of academic impact, for papers by A Akesson Breakdown of academic impact, for papers by Zora Marjanovic Breakdown of academic impact, for papers by Giovanni Pomponio Breakdown of academic impact, for papers by P Maddison Breakdown of academic impact, for papers by Carina Mihai Breakdown of academic impact, for papers by Alain Le Quellec
Rankless by CCL
2026